Clinical data | |
---|---|
Trade names | Invirase, Fortovase |
Other names | SQV |
AHFS/Drugs.com | Monograph |
MedlinePlus | a696001 |
License data |
|
Pregnancy category |
|
Routes of administration | By mouth |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | ~4% (without ritonavir boosting)[3] |
Protein binding | 98% |
Metabolism | Liver, mainly by CYP3A4 |
Elimination half-life | 9–15 hours |
Excretion | feces (81%) and urine (3%) |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
NIAID ChemDB | |
PDB ligand | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C38H50N6O5 |
Molar mass | 670.855 g·mol−1 |
3D model (JSmol) | |
| |
| |
(verify) |
Saquinavir, sold under the brand name Invirase among others, is an antiretroviral medication used together with other medications to treat or prevent HIV/AIDS.[4] Typically it is used with ritonavir or lopinavir/ritonavir to increase its effect.[4] It is taken by mouth.[4]
Common side effects include nausea, vomiting, diarrhea, and feeling tired.[4] More serious side effects include problems with QT prolongation, heart block, high blood lipids, and liver problems.[4] It appears to be safe in pregnancy.[4] It is in the protease inhibitor class and works by blocking the HIV protease.[4]
Saquinavir was patented in 1988 and first sold in 1995.[5][6]